Trials / Completed
CompletedNCT03871088
N-3 Fatty Acids as the First-line Antidepressant Therapy: From Biomarkers to Clinical Subtypes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- National Science and Technology Council, Taiwan · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Investigate the clinical subtypes and the biological markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD.
Detailed description
In this proposal, the investigators aim to explore the clinical subtypes and biological markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD. By stratifying the subjects with (versus without) remission and treatment response, the biological markers are expected to have important prediction effects in future clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Omega-3 fatty acids | 12-week double-blind, randomized controlled trial |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2018-06-01
- Completion
- 2018-12-01
- First posted
- 2019-03-12
- Last updated
- 2019-03-12
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03871088. Inclusion in this directory is not an endorsement.